Medicine and HealthNature Communications
Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice
A. S. Ashhurst, M. D. Johansen, et al.
Current vaccines against SARS-CoV-2 significantly reduce mortality, but infection protection remains inadequate. This research, conducted by Anneliese S Ashhurst and colleagues, explores a novel mucosal subunit vaccine that enhances respiratory tract immunity, promising better defense against the virus and minimizing viral spread.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice
A. A. Ordonez, C. K. Bullen, et al.
Medicine and Health
SARS-CoV-2 vaccination, booster, and infection in pregnant population enhances passive immunity in neonates
E. A. Murphy, C. Guzman-cardozo, et al.
Medicine and Health
SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals
K. Sano, D. Bhavsar, et al.
Medicine and Health
COVID-19 vaccination boosts the potency and breadth of the immune response against SARS-CoV-2 among recovered patients in Wuhan
H. Liang, X. Nian, et al.
